$EHC · Encompass Health Corp
Encompass Health filed its Q3 FY2026 10-Q, reporting net operating revenues of $1.609B (+8.9% YoY) and diluted EPS of $1.50, up from $1.24 in the prior-year quarter. Net income attributable to Encompass Health reached $149.9M, an 18.5% increase. Operating margins benefited from salary and benefits leverage (52.2% of revenue vs 53.1% a year ago), while D&A rose 16.1% reflecting ongoing capacity investments.
- Q3 net operating revenues rose 8.9% YoY to $1.609B, with nine-month revenues up 9.2% to $4.794B.
- Diluted EPS from continuing operations was $1.51 vs $1.24 a year ago; net income attributable to EHC hit $149.9M (+18.5% YoY).
- Salaries and benefits as a percentage of revenue improved to 52.2% from 53.1%, reflecting operating leverage.
- Medicare payor mix increased to 66.3% of revenues from 64.1%, while Medicare Advantage declined to 15.7% from 16.6%.
- Depreciation and amortization jumped 16.1% YoY to $95.7M, signaling ongoing capacity expansion.
Stock down 0.29% since filing ($136.34 at filing vs $135.96 now), a muted reaction to solid beats on both top and bottom lines — suggesting the strong quarter was largely priced in for this $13.41B market-cap name.
Encompass Health posted broad-based beats with 8.9% revenue growth and 18.5% net income expansion, but the stock barely moved — signaling the market had already priced in strong inpatient rehab demand.
Encompass Health's 8.9% revenue growth outpaces typical post-acute care peers, driven by favorable Medicare mix shift and volume gains. The expanding D&A line suggests continued de novo hospital construction, a capital-intensive growth strategy that differentiates it from acquisition-focused competitors.
Medicare concentration risk is rising: Medicare fee-for-service now represents 66.3% of revenues (up from 64.1%), increasing exposure to regulatory reimbursement changes. Labor cost inflation and staffing shortages remain flagged as persistent operational headwinds.